The Latest Wegovy News: What Has Changed in 2026

Step 1, The 7.2mg pen approval (January and April 2026)

The first piece of Wegovy news to land in 2026 arrived on 12 January, when the MHRA approved a 7.2mg maintenance dose of semaglutide. At that point it was supplied as three 2.4mg pens used across a single week, functional, but not exactly streamlined. The cleaner solution followed on 14 April 2026, when the MHRA licensed a dedicated single-dose 7.2mg pen: one pre-set injection per week, with an auto-dosing mechanism, a built-in covered needle and a lock that engages after use.

The clinical rationale matters here. Trial data at the 7.2mg dose reported an average weight loss of around 20.7% over 72 weeks, a figure that begins to close the gap on tirzepatide 15mg results. The licence for the single-dose pen applies to adults with a BMI of 30 or above; it is not authorised for BMI below 30 or for the cardiovascular indication. Starting dose remains 0.25mg, escalating roughly every four weeks under prescriber guidance up to the new maximum. The MHRA announcement on GOV.UK sets out the full detail for anyone who wants to read the regulator's own words.

One misconception worth letting go: many people assume a higher dose automatically means better results for everyone. In practice, the right dose is the one a prescriber chooses based on tolerability and response, not the highest one available. That decision sits with your clinical team, not the approval headline.

Step 2, The first oral GLP-1 for weight management in the UK (June 2026)

On 11 June 2026 the MHRA approved Wegovy tablets, making the UK the first country in Europe to license an oral GLP-1 medicine for weight management. This is the same active ingredient as the injection (semaglutide) reformulated with an absorption enhancer called SNAC so it can survive the digestive tract and reach the bloodstream via the stomach lining.

The dosing schedule runs from 1.5mg daily up through 4mg and 9mg to a 25mg maintenance dose, spending at least one month at each level. It is taken first thing in the morning on an empty stomach with a small amount of plain water, and you wait at least 30 minutes before eating, drinking anything else or taking other oral medicines. No refrigeration is needed, which makes it considerably more travel-friendly than the injection. You can read more about how the tablet works and who it suits on the semaglutide overview page.

Trial evidence came from the OASIS 4 study (307 adults, 64 weeks, versus placebo): average weight loss was around 13.6% regardless of adherence, rising to roughly 17% among participants who stayed fully adherent throughout the trial. That 17% figure needs its context, it represents the best-case adherent group, not an average for everyone who starts the tablet. Most side effects were gastrointestinal, mild to moderate, and generally settled as the body adjusted. The side effects of Wegovy page covers what to expect in detail. Wegovy tablets are not available on the NHS at launch, a NICE appraisal would be required first, so private prescription is currently the only route.

Step 3 (A new licensed indication: MASH (July 2026)

The most recent development in the Wegovy news cycle arrived on 3 July 2026, when the MHRA granted conditional approval for semaglutide (Wegovy) to treat metabolic dysfunction-associated steatohepatitis) MASH, a form of fatty liver disease characterised by inflammation and, in more advanced cases, fibrosis. The licence covers adults with moderate-to-advanced fibrosis. Full details are published in the MHRA announcement on GOV.UK from 3 July 2026.

For most readers visiting this page, the MASH approval is background context rather than a direct consideration: nume prescribes Wegovy for weight management, and the eligibility criteria for that indication remain unchanged. What the approval does signal is the broadening clinical evidence base for semaglutide as a medicine with effects well beyond appetite alone. The semaglutide news page tracks the wider evidence picture, including cardiovascular data.

If you are already on Wegovy and have questions about what these approvals mean for your current treatment, the right conversation is with your prescriber. Nothing in a regulatory announcement changes an individual's dose or schedule without a clinical review. Our FAQs page also covers common questions about continuing treatment.

What this means if you are thinking about starting Wegovy now

The practical upshot of all this wegovy latest news is choice: injection or tablet, 2.4mg or 7.2mg maintenance, depending on your circumstances and what a prescriber considers appropriate. The Wegovy treatment page sets out the current options in plain terms. Cost context is worth understanding too, comparing Wegovy prices in the UK shows that legitimate private pricing reflects clinical assessment, prescription issuance, and genuine supply-chain sourcing. Any quote that seems disconnected from those realities deserves scrutiny.

NICE's recommendation for injectable semaglutide (TA875) requires treatment within a specialist weight management service for a maximum of two years; those criteria apply to NHS access. Private routes follow the licensed eligibility criteria from the SmPC directly. If you are curious whether you meet those criteria, our prescribers review consultations the same day they are submitted. Check your eligibility by starting your free consultation, there is no obligation and no charge for the assessment itself.